新生血管性青光眼闭角期患者房水细胞因子变化及其与复发的关系
前瞻性病例对照研究纳入32例闭角期新生血管性青光眼(NVG)患者,接受抗VEGF注射、小梁切除术和全视网膜光凝三联序贯治疗并随访至少12个月。抗VEGF治疗前房水中VEGF、PD-L1、fractalkine、IL-7、eotaxin和TRAIL浓度显著高于增生型糖尿病视网膜病变和年龄相关性白内障对照组(均P<0.05)。6例复发患者治疗前房水IL-7浓度显著低于未复发患者(Z=-2.74,P<0.01)。
要点
- 闭角期NVG发病时房水VEGF、PD-L1、fractalkine、IL-7、eotaxin和TRAIL浓度明显增高。
- 抗VEGF治疗前和复发时房水VEGF浓度均高于PDR组和白内障组(均P<0.05)。
- 治疗前房水IL-7浓度低的NVG患者更容易复发。
核心结论
- 闭角期NVG患者房水中VEGF、PD-L1、fractalkine、IL-7、eotaxin和TRAIL在发病时都表现为明显增高,治疗前房水IL-7浓度低的患者更容易复发。
研究设计与样本
- 前瞻性病例对照研究,纳入2018年9月至2019年9月北京大学第三医院32例(32只眼)闭角期NVG患者,随访至少12个月。
- NVG患者接受包含抗VEGF药物注射、小梁切除术和全视网膜光凝的三联序贯治疗。
- 以25例增生型糖尿病视网膜病变(PDR)患者和24例年龄相关性白内障患者作为疾病对照组。
- 采用流式点阵免疫发光法检测45种细胞因子浓度,NVG组与对照组比较采用Kruskal-Wallis H检验,复发与未复发患者比较采用Mann-Whitney U检验。
主要发现
- NVG组抗VEGF治疗前、小梁切除术前、复发时房水VEGF浓度分别为2151.3(1433.1,4280.0)、655.4(287.3,836.3)、2003.4(1603.1,2468.9)ng/L。
- NVG组抗VEGF治疗前和复发时VEGF浓度均高于PDR组453.8(189.9,595.8)ng/L和白内障组143.5(112.7,269.8)ng/L(均P<0.05)。
- NVG组抗VEGF治疗前PD-L1为38.9(22.4,50.6)ng/L,高于PDR组12.0(6.3,20.1)ng/L和白内障组14.6(11.4,19.3)ng/L(均P<0.05)。
- NVG组抗VEGF治疗前fractalkine为242.7(189.0,306.7)ng/L、IL-7为18.0(12.0,32.7)ng/L、eotaxin为84.0(52.4,122.7)ng/L,均高于PDR组和白内障组(均P<0.05)。
- NVG组抗VEGF治疗前TRAIL为3.6(2.8,6.4)ng/L,高于白内障组1.1(0.3,2.3)ng/L(P<0.05);6例复发患者治疗前IL-7为10.5(8.4,16.0)ng/L,低于未复发患者22.7(15.7,34.1)ng/L(Z=-2.74,P<0.01)。
关键数值与推荐
- NVG组年龄(60±11)岁,男性22例,女性10例,年龄和性别分布与两个疾病对照组相比差异均无统计学意义(均P>0.05)。
- NVG组上述细胞因子其他阶段以及其他细胞因子不同阶段与两个疾病对照组比较差异均无统计学意义(均P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the concentration of cytokines in the aqueous humor of neovascular glaucoma (NVG) patients at the angle-closure stage in different treatment periods and its relationship with recurrence. Methods: A prospective case-control study. Angle-closure stage NVG patients who came to Peking University Third Hospital from September 2018 to September 2019 were enrolled and followed-up for at least 12 months. Patients received triple sequential therapy, including anti-vascular endothelium growth factor (VEGF) injection, trabeculectomy, and panretinal photocoagulation. The aqueous humor before anti-VEGF treatment, before trabeculectomy, and during recurrence was collected. Multiplex bead immunoassay was applied to measure the concentration of 45 cytokines including VEGF, interleukin (IL), and chemokine. The relevant data were compared with the values of 25 proliferative diabetic retinopathy (PDR) patients and 24 age-related cataract patients undergoing phacoemulsification as controls. The concentration of cytokines was presented as M (Q1, Q3). The nonparametric Kruskal-Wallis H test was applied to compare the cytokine concentration between the NVG group and controls. The difference between the recurrence and non-recurrence groups was compared with the Mann-Whitney U test. Results: The average age of NVG patients was (60±11) years, and there were 22 males and 10 females. No significant differences were found in age and gender between the NVG group and the two control groups (both P>0.05). The median concentrations of VEGF in the NVG group before anti-VEGF treatment, before trabeculectomy, and after recurrence were 2 151.3 (1 433.1, 4 280.0) ng/L, 655.4 (287.3, 836.3) ng/L and 2 003.4 (1 603.1, 2 468.9) ng/L respectively. The concentrations of VEGF before anti-VEGF treatment and after recurrence in the NVG group were significantly higher than the PDR group [453.8 (189.9, 595.8) ng/L] and the cataract group [143.5 (112.7, 269.8) ng/L] (all P<0.05). The median concentration of programmed cell death protein ligand 1 (PD-L1) was 38.9 (22.4, 50.6) ng/L before anti-VEGF treatment, higher than that in the PDR group [12.0 (6.3, 20.1) ng/L] and the cataract group [14.6 (11.4, 19.3) ng/L]. The median concentration of fractalkine was 242.7 (189.0, 306.7) ng/L, higher than that in the PDR group [131.1 (119.1, 157.6) ng/L] and the cataract group [116.7 (10.2, 135.9) ng/L]. The median concentration of IL-7 was 18.0 (12.0, 32.7) ng/L, higher than that in the PDR group [7.7 (2.0, 10.8) ng/L] and the cataract group [3.3 (1.9, 6.8) ng/L]. The median concentration of eotaxin was 84.0 (52.4, 122.7) ng/L, higher than that in the PDR group [26.6 (17.1, 72.3) ng/L] and the cataract group [7.1 (5.6, 14.8) ng/L]. The median concentration of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was 3.6 (2.8, 6.4) ng/L, higher than that in the cataract group [1.1 (0.3, 2.3) ng/L]. All the differences were statistically significant (all P<0.05). There were no significant differences between the NVG and control groups in other cytokines or other treatment periods (all P>0.05). Six NVG patients suffered recurrence during the follow-up. The baseline concentration of IL-7 of these patients [10.5 (8.4, 16.0) ng/L] was significantly lower than that in patients who did not have recurred disease [22.7 (15.7, 34.1) ng/L] (Z=-2.74, P<0.01). Conclusions: In the angle-closure stage of NVG patients, the concentrations of VEGF, PD-L1, fractalkine, IL-7, eotaxin, and TRAIL in the aqueous humor significantly increase during the onset of disease. Lower IL-7 may indicate a recurring tendency. 目的: 评估新生血管性青光眼(NVG)闭角期患者房水内细胞因子浓度的变化并分析其与复发的关系。 方法: 前瞻性病例对照研究。收集2018年9月至2019年9月就诊于北京大学第三医院眼科的32例(32只眼)NVG闭角期患者(NVG组),所有患者均接受包含抗血管内皮生长因子(VEGF)药物注射、小梁切除术和全视网膜光凝在内的三联序贯治疗并随访至少12个月。NVG组患者在抗VEGF药物注射前、小梁切除术前及NVG复发时收集房水标本,采用流式点阵免疫发光法检测VEGF、白细胞介素(IL)、趋化因子等45种细胞因子的浓度。选取25例增生型糖尿病视网膜病变(PDR)患者(PDR组)和24例年龄相关性白内障患者(白内障组)作为疾病对照组。细胞因子浓度以M(Q1,Q3)表示,NVG组与疾病对照组间细胞因子浓度比较采用非参数Kruskal-Wallis H检验;NVG复发与未复发患者间细胞因子浓度比较采用Mann-Whitney U检验。 结果: NVG组年龄(60±11)岁,男性22例,女性10例;年龄和性别分布与两个疾病对照组相比差异均无统计学意义(均P>0.05)。NVG组在抗VEGF治疗前、小梁切除术前、复发时房水中VEGF浓度分别为2 151.3(1 433.1,4 280.0)、655.4(287.3,836.3)、2 003.4(1 603.1,2 468.9)ng/L,抗VEGF治疗前和复发时均高于PDR组[453.8(189.9,595.8)ng/L]和白内障组[143.5(112.7,269.8)ng/L],差异均有统计学意义(均P<0.05)。NVG组在抗VEGF治疗前房水中细胞程序性死亡蛋白-配体1(PD-L1)浓度[38.9(22.4,50.6)ng/L]高于PDR组[12.0(6.3,20.1)ng/L]和白内障组[14.6(11.4,19.3)ng/L];CX3C型趋化因子配体1(fractalkine)浓度[242.7(189.0,306.7)ng/L]高于PDR组[131.1(119.1,157.6)ng/L]和白内障组[116.7(10.2,135.9)ng/L];IL-7浓度[18.0(12.0,32.7)ng/L]高于PDR组[7.7(2.0,10.8)ng/L]和白内障组[3.3(1.9,6.8)ng/L];嗜酸粒细胞趋化因子(eotaxin)浓度[84.0(52.4,122.7)ng/L]高于PDR组[26.6(17.1,72.3)ng/L]和白内障组[7.1(5.6,14.8)ng/L];肿瘤坏死因子相关凋亡诱导配体(TRAIL)浓度[3.6(2.8,6.4)ng/L]高于白内障组[1.1(0.3,2.3)ng/L],差异均有统计学意义(均P<0.05)。NVG组上述细胞因子其他阶段以及其他细胞因子不同阶段与两个疾病对照组比较差异均无统计学意义(均P>0.05)。6例NVG患者在随访期复发,复发患者在抗VEGF治疗前房水中IL-7浓度为10.5(8.4,16.0)ng/L低于未复发患者治疗前的22.7(15.7,34.1)ng/L,差异有统计学意义(Z=-2.74;P<0.01)。 结论: NVG闭角期患者房水中VEGF、PD-L1、fractalkine、IL-7、eotaxin和TRAIL在发病时都表现为明显增高。治疗前房水IL-7浓度低的患者更容易复发。.
引用
- Hong Y, Chen XH, Wu QR, et al. [Changes of cytokines in the aqueous humor of neovascular glaucoma at the angle-closure stage]. Zhonghua Yan Ke Za Zhi. 2022. PMID: 34979788. doi:10.3760/cma.j.cn112142-20210514-00229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。